Follow The Filings

NUVB Nuvation Bio Inc.

Health Care, filed as NUVATION BIO INC (COM CL A), Equity As of 2026 Q3 so far: 135 of 140 managers we track have filed Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q3, sold by 1

  • 5 Owners
  • Max 0.3%
  • $23M
  • 1 new 1 reduce

In 2026 Q3 Torray Investment Partners opened a position in Nuvation Bio, while Stanley Druckenmiller trimmed.

Who owns this now

Largest portfolio weights among holders, up to 0.3% (Stanley Druckenmiller, Duquesne Family Office). Not free-float ownership.

  1. Stanley Druckenmiller Reduce 0.28%
  2. Palo Alto Investors 0.27%
  3. Torray Investment Partners New 0.20%
  4. David Abrams 0.15%
  5. David Einhorn 0.01%

Who owns NUVB

Sorted by value, long equity only, as of 2026 Q3.

History
Stanley Druckenmiller, Duquesne Family Office 0.28%, was 0.49% Reduce −50.0% 2,269,900 $13M History
David Abrams, Abrams Capital Management 0.15% Hold 1,270,504 $7.1M History
Palo Alto Investors 0.27% Hold 326,609 $1.8M History
Torray Investment Partners 0.20% New 0.20% 274,814 $1.5M History
David Einhorn, DME Capital Management 0.01% Hold 34,995 $196K History

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by NUVB's executives, directors and 10% owners in the last 12 months, from their Form 4s

All NUVB insider trades
  • $118K bought by 1 insider
  • $1.3M sold by 1 insider outside a trading plan
  • $3.5M sold by 5 insiders under 10b5-1 plans
  1. Gary Hattersley Chief Scientific Officer
    Planned sale
    $709K 100,000 shares at $7.09 100% of stake
    Traded Aug 19 Filed Aug 21
  2. Philippe Sauvage CFO
    Planned sale
    $286K 47,668 shares at $6.01 79% of stake
    Traded Jun 23 Filed Jun 24
  3. Stacy Markel Chief People Officer
    Planned sale
    $753K 125,000 shares at $6.03 79% of stake
    Traded Jun 23 Filed Jun 24
  4. Kerry Wentworth Chief Regulatory Officer
    Planned sale
    $379K 63,000 shares at $6.02 54% of stake
    Traded Jun 23 Filed Jun 24
  5. Robert Mashal Director
    Buy
    $118K 25,000 shares at $4.73 +13% to stake
    Traded Jun 9 Filed Jun 11
  6. Dongfang Liu Chief Medical Officer
    Planned sale
    $251K 50,000 shares at $5.02 74% of stake
    Traded Apr 17 Filed Apr 21
  7. Kerry Wentworth Chief Regulatory Officer
    Planned sale
    $184K 36,750 shares at $5.01 41% of stake
    Traded Apr 17 Filed Apr 21
  8. Kerry Wentworth Chief Regulatory Officer
    Planned sale
    $904K 200,000 shares at $4.52 79% of stake
    Traded Apr 6 Filed Apr 8
  9. Dongfang Liu Chief Medical Officer
    Sale
    $1.2M 150,000 shares at $7.82 89% of stake
    Traded Dec 1, 2025 Filed Dec 3, 2025
  10. Dongfang Liu Chief Medical Officer
    Sale
    $155K 20,000 shares at $7.75 53% of stake
    Traded Nov 25–26 Filed Nov 26, 2025
  11. Dongfang Liu Chief Medical Officer
    Sale
    $140K 20,000 shares at $7.00 53% of stake
    Traded Nov 20, 2025 Filed Nov 24, 2025
  12. Gary Hattersley Chief Scientific Officer
    Sale
    $2.7M 369,051 shares at $7.23 100% of stake
    Traded Nov 20, 2025 Filed Nov 24, 2025
  13. David C. Hanley Chief Technical Operations
    Sale
    $1.4M 200,000 shares at $7.14 89% of stake
    Traded Nov 19, 2025 Filed Nov 21, 2025
  14. Dongfang Liu Chief Medical Officer
    Sale
    $148K 30,000 shares at $4.93 63% of stake
    Traded Nov 17–19 Filed Nov 19, 2025
  15. Gary Hattersley Chief Scientific Officer
    Planned sale
    $502K 100,000 shares at $5.02 100% of stake
    Traded Oct 27, 2025 Filed Oct 29, 2025

Also filed in the last 12 months, not counted as buying or selling: 14 option exercises and 1 stock grant.

SEC filings

Recent issuer filings from EDGAR, 14 shown.

Filed Form Detail Links
10-Q
8-K 2.02,9.01
10-Q
8-K 2.02,9.01
8-K 2.03,8.01,9.01
8-K 1.01,1.02,2.03,8.01,9.01
424B5
424B5
8-K 5.07
10-Q
8-K 2.02,9.01
DEFA14A
DEF 14A
10-K

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue — $7.87M $62.9M
Gross profit — $795,000 —
Gross margin * — 10.1% —
Net income -$75.8M -$567.94M -$204.63M
Net margin * — -7213.8% -325.3%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $616.43M $526.26M $571.52M
Total non-current assets * $5.05M $14.37M $23.3M
Total assets $621.48M $540.63M $594.82M
Total current liabilities $13.97M $58.24M $82.23M
Total non-current liabilities * $2.39M $18.59M $206.88M
Total equity $605.12M $463.79M $305.72M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$68M -$130.41M -$173.43M
Cash from investing $8.92M $122.7M $99.52M
Cash from financing $0.628M $0.331M $202.54M
Net change in cash -$58.45M -$6.93M $128.36M

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf